Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given
in combination to men with metastatic hormone refractory prostate cancer and to assess the
pharmacokinetic interactions between the 2 drugs.